Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Merck
McKinsey
McKesson
Colorcon

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SPRYCEL

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for SPRYCEL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00162214 Study of Dasatinib in Patients With Advanced Solid Tumors Terminated Bristol-Myers Squibb Phase 1 2005-08-01 The purpose of Segment 1 of the study is to determine the effect of ketoconazole on dasatinib. The purpose of Segment 2 is to learn how dasatinib affects tumor growth in patients with advanced solid tumors.
NCT00255346 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Active, not recruiting Bristol-Myers Squibb Phase 2 2005-11-01 The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
NCT00255346 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Active, not recruiting M.D. Anderson Cancer Center Phase 2 2005-11-01 The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
NCT00371345 Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer Completed Bristol-Myers Squibb Phase 2 2006-12-01 This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer
NCT00481247 A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Completed Bristol-Myers Squibb Phase 3 2007-09-01 The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase Philadelphia positive chronic myeloid leukemia. The safety of this treatment will also be studied.
NCT00538980 Dasatinib in Polycythemia Vera Completed Bristol-Myers Squibb Phase 2 2007-04-01 The purpose for conducting this research study is to determine the feasibility of using dasatinib as a treatment for polycythemia vera and to determine the optimum treatment regimen.
NCT00538980 Dasatinib in Polycythemia Vera Completed Weill Medical College of Cornell University Phase 2 2007-04-01 The purpose for conducting this research study is to determine the feasibility of using dasatinib as a treatment for polycythemia vera and to determine the optimum treatment regimen.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SPRYCEL

Condition Name

Condition Name for SPRYCEL
Intervention Trials
Breast Cancer 4
Leukemia 4
Glioblastoma 3
Chronic Myeloid Leukemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for SPRYCEL
Intervention Trials
Leukemia 25
Leukemia, Myeloid 19
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18
Breast Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for SPRYCEL

Trials by Country

Trials by Country for SPRYCEL
Location Trials
United States 157
Spain 12
Japan 11
France 9
China 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for SPRYCEL
Location Trials
Texas 16
New York 10
Pennsylvania 9
North Carolina 9
Florida 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for SPRYCEL

Clinical Trial Phase

Clinical Trial Phase for SPRYCEL
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 2 25
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for SPRYCEL
Clinical Trial Phase Trials
Completed 19
Recruiting 10
Terminated 8
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for SPRYCEL

Sponsor Name

Sponsor Name for SPRYCEL
Sponsor Trials
Bristol-Myers Squibb 27
M.D. Anderson Cancer Center 11
National Cancer Institute (NCI) 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for SPRYCEL
Sponsor Trials
Other 47
Industry 37
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Mallinckrodt
McKinsey
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.